3SBio Inc. (SEHK: 1530)
Health Care · Biotechnology · CN
HK$15.07
+0.53% today · -47.3% 1Y
3SBio Inc. (SEHK: 1530) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.79B and employs 6,068 people.
Over the last twelve months the share price has lost 47.3%, trading between 14.81 and 35.42.
Tweenvest scores 3SBio Inc. across four factors: quality 78/100, value 67/100, growth 98/100, dividend 37/100. Its strongest factor is growth.
1530 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.79B
- Revenue (TTM)
- $2.63B
- P/E
- 4.02
- EPS
- 3.25
- Dividend yield
- 1.67%
- Beta (5Y)
- 0.40
- 52-week high
- HK$35.42
- 52-week low
- HK$14.81
- Avg volume (3M)
- —
- Shares outstanding
- 2.49B
- Employees
- 6,068
- Next earnings
- —
About 3SBio Inc.
Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
- ISIN
- KYG8875G1029
- Founded
- 1993
- Listed since
- Jun 11, 2015
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.SHSE: 603392 | $5.09B | CN¥26.96 | -1.39% |
| Shanghai RAAS Blood Products Co., Ltd.SZSE: 002252 | $4.98B | CN¥5.06 | -4.89% |
| Travere Therapeutics, Inc.NasdaqGM: TVTX | $4.91B | $52.52 | +0.76% |
| Chongqing Zhifei Biological Products Co., Ltd.SZSE: 300122 | $4.90B | CN¥13.70 | -2.00% |
| Dianthus Therapeutics, Inc.NasdaqCM: DNTH | $4.61B | $82.42 | +0.06% |
| Lin BioScience, Inc.TPEX: 6696 | $4.54B | NT$175.00 | -3.58% |
| Shanghai Junshi Biosciences Co., Ltd.SEHK: 1877 | $4.45B | HK$17.65 | -2.32% |
| Imeik Technology Development Co.,Ltd.SZSE: 300896 | $4.28B | CN¥95.03 | -0.16% |
Figures last refreshed Oct 11, 2026.